Balaxi Pharmaceuticals Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Ashish Maheshwari
Chief executive officer
₹8.3m
Total compensation
| CEO salary percentage | 96.97% |
| CEO tenure | 8yrs |
| CEO ownership | 1.8% |
| Management average tenure | 5.3yrs |
| Board average tenure | 8yrs |
Recent management updates
Recent updates
Balaxi Pharmaceuticals (NSE:BALAXI) May Have Issues Allocating Its Capital
May 01
Balaxi Pharmaceuticals Limited (NSE:BALAXI) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Feb 19Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?
Jan 21Balaxi Pharmaceuticals (NSE:BALAXI) Strong Profits May Be Masking Some Underlying Issues
Nov 13These 4 Measures Indicate That Balaxi Pharmaceuticals (NSE:BALAXI) Is Using Debt Reasonably Well
Jul 30Balaxi Pharmaceuticals Limited's (NSE:BALAXI) Share Price Could Signal Some Risk
May 29Market Might Still Lack Some Conviction On Balaxi Pharmaceuticals Limited (NSE:BALAXI) Even After 38% Share Price Boost
Feb 10Balaxi Pharmaceuticals (NSE:BALAXI) Has A Pretty Healthy Balance Sheet
Feb 09Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?
Aug 08The Trend Of High Returns At Balaxi Pharmaceuticals (NSE:BALAXI) Has Us Very Interested
May 20A Look At The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)
Feb 03Calculating The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)
Sep 06Balaxi Pharmaceuticals (NSE:BALAXI) Knows How To Allocate Capital Effectively
Jun 03Is Weakness In Balaxi Pharmaceuticals Limited (NSE:BALAXI) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Mar 12Is Balaxi Pharmaceuticals Limited's(NSE:BALAXI) Recent Stock Performance Tethered To Its Strong Fundamentals?
Nov 27
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | ₹274m |
| Sep 30 2024 | n/a | n/a | ₹356m |
| Jun 30 2024 | n/a | n/a | ₹454m |
| Mar 31 2024 | ₹8m | ₹8m | -₹24m |
| Dec 31 2023 | n/a | n/a | -₹52m |
| Sep 30 2023 | n/a | n/a | -₹106m |
| Jun 30 2023 | n/a | n/a | -₹95m |
| Mar 31 2023 | n/a | n/a | ₹460m |
| Dec 31 2022 | n/a | n/a | ₹506m |
| Sep 30 2022 | n/a | n/a | ₹545m |
| Jun 30 2022 | n/a | n/a | ₹511m |
| Mar 31 2022 | ₹3m | ₹3m | ₹477m |
| Dec 31 2021 | n/a | n/a | ₹433m |
| Sep 30 2021 | n/a | n/a | ₹421m |
| Jun 30 2021 | n/a | n/a | ₹401m |
| Mar 31 2021 | ₹3m | ₹3m | ₹381m |
| Dec 31 2020 | n/a | n/a | ₹312m |
| Sep 30 2020 | n/a | n/a | ₹228m |
| Jun 30 2020 | n/a | n/a | ₹138m |
| Mar 31 2020 | ₹3m | ₹3m | ₹61m |
Compensation vs Market: Ashish's total compensation ($USD96.40K) is above average for companies of similar size in the Indian market ($USD42.14K).
Compensation vs Earnings: Ashish's compensation has been consistent with company performance over the past year.
CEO
Ashish Maheshwari (54 yo)
Mr. Ashish Maheshwari has been Managing Director and Executive Director of Balaxi Pharmaceuticals Limited (formerly known as Balaxi Ventures Limited) (formerly known as The Anandam Rubber Company Limited)...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Chairman | 8yrs | ₹8.25m | 1.78% ₹ 48.5m | |
| CFO & Financial Controller | 5.3yrs | no data | no data | |
| President Operations | no data | no data | no data | |
| Company Secretary & Compliance Officer | less than a year | no data | no data | |
| Senior Vice President of Business Development | 5.3yrs | no data | no data | |
| Head of Alternate Channels | 5.3yrs | no data | no data | |
| Finance Controller of Angola | no data | no data | no data | |
| Head of Operations of Guatemala | no data | no data | no data | |
| Head of Operations of Dominician Republic | no data | no data | no data | |
| Compliance Head of Angola | no data | no data | no data | |
| Sales Head of Guatemala | no data | no data | no data | |
| Sales Head of Dominician Republic | no data | no data | no data |
Experienced Management: BALAXI's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Chairman | 8yrs | ₹8.25m | 1.78% ₹ 48.5m | |
| Independent Non-Executive Director | 8yrs | ₹250.00k | 2.02% ₹ 55.2m | |
| Non-Executive Independent Director | less than a year | no data | no data | |
| Non Executive Director | 8yrs | ₹250.00k | 1.04% ₹ 28.3m | |
| Independent Non-Executive Director | 8yrs | ₹150.00k | no data | |
| Independent Non-Executive Director | 4.7yrs | ₹250.00k | 0.098% ₹ 2.7m |
Experienced Board: BALAXI's board of directors are considered experienced (8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 22:45 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Balaxi Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.